Fine Foods & Pharmaceuticals N.T.M. SpA

As of June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA carries a market capitalization of 197.00M, placing it among publicly traded companies globally. Its enterprise value stands at 294.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fine Foods & Pharmaceuticals N.T.M. SpA's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA has 22.70M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.81, and the price-to-book ratio stands at 1.70.

As of June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA trades at an EV/EBITDA multiple of 11.95 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 67.32 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 294.48M versus a market cap of 197.00M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA maintains a current ratio of 1.49, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 115.33, indicating elevated leverage, while an interest coverage ratio of 7.97 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA posted a negative return on equity (ROE) of -0.82, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) is negative at -1.64, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) is negative at -0.35, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -1.62, pointing to unprofitable operations over the period. The company generates approximately 301,118.50 in revenue per employee across its workforce of 824.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.19 indicates how many times Fine Foods & Pharmaceuticals N.T.M. SpA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA recorded 2.23M in income tax expense. That works out to an effective tax rate of 187.00, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.19M, leaving -1.04M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA's stock has declined approximately 32.76% over the past 52 weeks. The 50-day moving average sits at 7.46, while the 200-day moving average is 8.80.

Over the twelve months ended June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA generated 248.12M in revenue and converted that into -1.04M in net income, yielding earnings per share of -0.04. EBITDA reached 24.64M, while operating income came in at 9.29M.

As of June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA holds 36.34M in cash and equivalents against 133.82M in total debt, resulting in a net debt position of 110.75M. Total book value stands at 116.03M, with working capital of 45.21M providing operational flexibility.

Fine Foods & Pharmaceuticals N.T.M. SpA produced 32.42M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -30.63M in capital expenditures, free cash flow totaled 1.79M - equivalent to 0.08 per share.

Over the twelve months ended June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA posted a gross margin of 45.18, reflecting its pricing power and cost economics. The operating margin of 3.75 and net profit margin of -0.42 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 0.88, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -19.82, meaning Fine Foods & Pharmaceuticals N.T.M. SpA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Fine Foods & Pharmaceuticals N.T.M. SpA has an Altman Z-Score of 1.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.